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Morphine and other mu-opioid receptor (MOR) agonists remain the mainstay treatment of acute and 
prolonged pain states worldwide. The major limiting factor for continued use of these current opioids 
is the high incidence of side effects that result in loss of life and loss of quality of life. The development 
of novel opioids bereft, or much less potent, at inducing these side effects remains an intensive area 
of research, with multiple pharmacological strategies being explored. However, as with many G 
protein-coupled receptors (GPCRs), translation of promising candidates from in vitro characterisation 
to successful clinical candidates still represents a major challenge and attrition point. This review 
summarises the preclinical animal models used to evaluate the key opioid-induced behaviours of 
antinociception, respiratory depression, constipation and opioid-induced hyperalgesia and tolerance. 
We highlight the influence of distinct variables in the experimental protocols, as well as the potential 
implications for differences in receptor reserve in each system. Finally, we discuss how methods  to 
assess opioid action in vivo and in vitro relate to each other in the context of bridging the translational 
gap in opioid drug discovery.  
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Opioids are the gold standard for analgesic medications, both for acute severe pain and chronic pain 
management. Chronic pain in particular is a major health issue across the world today. Estimates of 
the prevalence of chronic pain range from 20 to 40% of the population in both developing (Sá, et al., 
2019) and developed (Dahlhamer, et al., 2018) countries, representing a significant societal and 
economic cost.  
Opioids still remain mainstay analgesics despite the suite of on-target side effects mediated by 
activation of the µ-opioid receptor (MOR), the primary target of most opioid pain medications 
(Matthes, et al., 1996). Two major side effects include respiratory depression and addiction. These 
side effects are, in many ways, the “face” of opioids (Okie, 2010), with respiratory depression being 
the cause of fatality in an overdose situation and opioid addiction being present in most, if not all, 
countries worldwide. In 2017, fatal opioid overdoses totalled over 60,000 in the USA (Hedegaard H, 
2017) and the number and rate of increase in overdose deaths was the highest in the UK since records 
began (Office of National Statistics, 2019). Additional side effects include constipation, due to opioid-
induced reduction in gut motility, and hyperalgesia, a condition where opioid use paradoxically 
induces a heightened sensitivity to pain (Benyamin, et al., 2008). These are still significant side effects 
that affect the quality of life and decrease patient compliance (Camilleri, 2011; Katz, 2002; Panchal, 
Mueller-Schwefe, & Wurzelmann, 2007).  
Intense research is currently addressing the urgent need for improved and safer analgesics,  either 
through the discovery and validation of new targets such as other cell surface receptors e.g. 
cannabinoid receptors (Vučković, Srebro, Vujović, Vučetić, & Prostran, 2018), voltage-gated sodium 
channels (Bennett, Clark, Huang, Waxman, & Dib-Hajj, 2019), targeted toxins (Yaksh, Woller, 
Ramachandran, & Sorkin, 2015) or through the development of new opioid receptor ligands with new 
mechanisms of action (Crombie, et al., 2015; Dekan, et al., 2019; DeWire, et al., 2013; Gassaway, Rives, 
Kruegel, Javitch, & Sames, 2014; Koblish, et al., 2017; Schmid, et al., 2017).  
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Early data from arrestin-3 KO mice suggested that with the removal of arrestin-3 morphine induced 
enhanced antinociception, with a reduced degree of respiratory depression (Raehal, Walker, & Bohn, 
2005). Since then, focus has been centred in the development of G protein-biased agonists to 
potentially retain the antinociceptive properties while avoiding the respiratory depressant effects 
(Dekan, et al., 2019; DeWire, et al., 2013; Gillis, Gondin, et al., 2020; Manglik, et al., 2016; Schmid, et 
al., 2017; Varadi, et al., 2016). Some novel opioids generated based on this hypothesis have resulted 
in marginally improved separation between the antinociceptive and respiratory depressant dose 
response curves (DeWire, et al., 2013; Gillis, Gondin, et al., 2020; Schmid, et al., 2017). However, the 
mechanisms responsible for this wider therapeutic windows are still unclear (Azevedo Neto, et al., 
2020; Bachmutsky, Durand, et al., 2020; Haouzi, et al., 2021; Kliewer, et al., 2020; Kliewer, et al., 2019).  
Other strategies to develop improved opioid analgesics target other opioid receptor subtypes. k-
Opioid receptor (KOR) agonists have been shown to provide effective antinociception without 
inducing respiratory depression. However, the dysphoria associated with KOR agonism limits their 
clinical utility (Chavkin & Koob, 2016). Several reports suggest that dysphoria is induced predominantly 
by activation of an arrestin-mediated signalling pathway (Brust, et al., 2017; Lovell, et al., 2017) 
suggesting the development of G-protein biased KOR agonists as a potential strategy to develop new 
analgesics. Unfortunately, attempts to obviate KOR-induced dysphoria whilst producing an 
appreciable level of antinociception have not translated into therapies as yet (Mores, Cummins, 
Cassell, & van Rijn, 2019). There has also been an increasing body of evidence suggesting that the d-
opioid receptor (DOR) may be an attractive target for specific modalities of pain such as chronic 
inflammatory or neuropathic pain (A. A. Pradhan, Befort, Nozaki, Gavériaux-Ruff, & Kieffer, 2011). 
However, interest in DOR therapeutics has been limited due to pro-convulsive activity exhibited by 
certain DOR agonists (Broom, et al., 2002), as well as an apparent greater liability for tolerance (A. A. 
A. Pradhan, et al., 2010). Attempts to alleviate these side effects are ongoing (Audet, et al., 2012; 
Charfi, Audet, Bagheri Tudashki, & Pineyro, 2015; Alexandra E. Conibear, et al., 2020). Additionally, 
beyond the three classical MOR, KOR and DOR subtypes, the nociceptin opioid peptide receptor (NOP) 
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is actively pursued as a potential target for novel analgesic therapeutics (Zaveri, 2016); the widespread 
expression of NOP and its upregulation in chronic pain states suggest a potential role for NOP 
antagonists in pain therapy (Calo & Lambert, 2018; Zaveri, 2016). Indeed, molecules that combine a 
MOR and NOP partial agonist mode of action have been shown to provide antinociception in the 
absence of side effects in nonhuman primates (Ding, et al., 2018). 
The paucity of novel opioid-based analgesics reaching the bedside reflects a general attrition in G 
protein-coupled receptors (GPCR) drug discovery programmes. Translation of candidate molecules 
from in vitro pharmacological characterisation into pre-clinical and clinical settings still represents a 
significant hurdle. Differences in experimental conditions, both in vitro and in animal models, are likely 
to underlie this translational challenge.  
This review examines the preclinical animal models used to evaluate the key opioid-induced 
behaviours. We consider the influence of distinct variables in the experimental protocols, as well as 
the potential implications for differences in receptor reserve in each system. Finally, we discuss how 
the methods to assess opioid action in vivo and in vitro relate to each other in the context of bridging 
the translational gap in opioid drug discovery (Figure 1). In particular, we focus on the methods used 
to assess opioid-induced antinociception, respiratory depression, constipation, hyperalgesia and 
tolerance in the drug discovery setting. While the rewarding, addictive and consequent withdrawal 
effects associated with opioid use are major side effects, their complex and multi-faceted nature as 
well as the myriad of approaches used to investigate them are outside the scope of this review. The 
mechanisms underlying these behaviours, as well as the methods used to study them in preclinical 
models are elegantly reviewed elsewhere (Banks & Negus, 2017; Charbogne, Kieffer, & Befort, 2014; 
Kreek, et al., 2012; Negus & Moerke, 2019; Rodríguez-Arias, Aguilar, Manzanedo, & Miñarro, 2010; 
Sadee, Oberdick, & Wang, 2020; Swain, Gewirtz, & Harris, 2021) 
2- Assessment of opioid-induced antinociception 
 7 
Antinociception refers to the inhibition of the detection of a painful stimulus by nociceptive (pain) 
neurons. In contrast, the term analgesia is used when referring to the alleviation of the experience of 
pain, which includes not only the inhibition of nociceptive signalling but also a subjective component 
that cannot be assessed in animal models. As such, the term antinociception is used to indicate the 
reductions in pain state observed in nonhuman animals, where an assessment of the subjective 
component is not possible. The most widely used in vivo models of antinociception involve a pain 
stimulus (physical activation of nociceptive fibre) being delivered to the animal to elicit a pain 
behaviour and the subsequent measurement of the reduction of such pain behaviours by analgesic 
agents. Thermal nociception tests are commonly used in the discovery and characterisation of opioid 
compounds with the hot plate assay and tail flick (or tail withdrawal) tests being regularly used as the 
first in vivo measurement of antinociceptive efficacy (Table 1). Other mechanical (e.g Von Frey, 
Hargreaves) and chemical (e.g formalin, complete Freund’s adjuvant) nociception assays are also used 
to evaluate antinociceptive efficacy of opioids in conditions such as inflammatory and neuropathic 
pain. 
Tail flick assay. The tail flick assay measures the latency required for an animal to remove or flick its 
tail from a heat source. It is typically used in rodents that are usually restrained (by scruffing, cupping, 
wrapping, or placed in a tube) when a heat stimulus is applied to the distal portion of the tail (D'Amour 
& Smith, 1941; Hardy, 1953; Hardy, Stoll, Cunningham, Benson, & Greene, 1957; Hardy, Wolff, & 
Goodell, 1940). The noxious heat stimulus can be immersion of the tail in warm water or application 
of radiant heat to a smaller section of the tail with greater heat intensity (i.e. non radiant heat) 
resulting in shorter reaction times (Carroll, 1959; Carstens & Wilson, 1993; Granat & Saelens, 1973; 
Levine, Murphy, Seidenwurm, Cortez, & Fields, 1980). Baseline tail-flick latency is typically 2-4 seconds 
(Raffa, et al., 1992). Importantly, this assay measures the lower cervical reflex arc responsible for the 
tail flick. It therefore monitors the response to a spinal reflex, rather than an indication of pain 
behaviours involving higher brain centres.  
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Hot plate assay. The hot plate assay measures behaviours that require central processing and are 
considered to integrate supraspinal pathways. It consists of the application of a thermal stimulus to 
the paws, tail and the dorsal flank of the animal and measures the latency for the animal to elicit a 
pain behaviour (Eddy & Leimbach, 1953; Ocallaghan & Holtzman, 1975; Woolfe & Macdonald, 1944). 
Typically unrestrained rodents are placed in a metal surface maintained at a constant temperature 
and manifestations of pain are seen as fluttering of the feet, rearing and licking forepaws/hindpaws, 
squirming to dissipate heat, and jumping (Carter, 1991).  
While both the tail flick and the hot plate assay provide useful information on the antinociceptive 
actions of opioids, there are obvious ethical considerations integral to the experiment that prevent 
unnecessary animal suffering, and yet ensure that the data remain valid and useable. Limits in the 
maximum temperature of the noxious stimulus (the thermal limit - typically 48-550C) and maximum 
latency cut-offs (i.e maximum time until response is observed, typically 10-30 sec) prevent damage to 
the tissues of the experimental animal (Table 1). It is also important to note that increased 
temperatures are associated with not just decreased latencies (Carroll, 1959; Carstens & Wilson, 1993; 
Ren & Han, 1979) but also associated reduced antinociceptive efficacy, namely, analgesics are less 
efficacious the higher the temperature (Ankier, 1974; Hunskaar, Berge, & Hole, 1986; Zimet, Wynn, 
Ford, & Rudo, 1986). In addition, ethical considerations also limit the frequency at which the test can 
be repeated in the same animal. This usually implies that data is acquired in 15-30 min bins, which 
impacts the temporal resolution of the assay and can affect determinations of peak effects and of 
pharmacokinetic profiles.  
The necessary cut-offs in antinociceptive assays have significant implications in estimations of in vivo 
agonist efficacy.  Antinociception is calculated as a percentage of the maximum possible effect (%MPE) 
which is calculated as follows: 
%𝑀𝑃𝐸 =	
𝑡𝑒𝑠𝑡	𝑙𝑎𝑡𝑒𝑛𝑐𝑦 − 𝑐𝑜𝑛𝑡𝑟𝑜𝑙	𝑙𝑎𝑡𝑒𝑛𝑐𝑦
𝑀𝑎𝑥. 𝑙𝑎𝑡𝑒𝑛𝑐𝑦 − 𝑐𝑜𝑛𝑡𝑟𝑜𝑙	𝑙𝑎𝑡𝑒𝑛𝑐𝑦
	× 100 
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where “test latency” is the latency measured for the test drug, “control latency” is the baseline latency 
and “Max latency” is the upper temporal limit established to prevent tissue damage. It follows that 
when the latency measured for the test drug equals or exceeds the maximum latency cut-off, the test 
compound will display 100% MPE. Thus, detection of differences of opioid antinociceptive efficacy 
beyond a certain threshold will be prevented. 
The above-mentioned cut-offs also have an impact on the determinations of antinociceptive potency, 
which in turn are important in the determination of therapeutic windows, where ED50s (the effective 
dose eliciting a 50% of the maximal response) between antinociception and other side effects are 
compared.  Similarly, they should be taken into account when different efficacies are observed 
between measurements of antinociception and of other opioid-induced side effects.  Thus, different 
temperatures and latency cut-offs being used can impact interpretations of effects across different 
studies (Table 1).  
There is significant accumulated evidence that shows that inbred strains of mice can vary significantly 
in their nociceptive sensitivity (Table 2) (Homanics, Quinlan, & Firestone, 1999; Mogil, et al., 1996). 
Differences across strains have been generally observed with regards to the baseline latencies and the 
antinociceptive responses of classical opioids such as morphine (Crain & Shen, 2000; Kest, Hopkins, 
Palmese, Adler, & Mogil, 2002; Mogil & Wilson, 1997). While such differences can be related to the 
different pharmacokinetics of opioid drugs in different strains, this remains to be systematically 
investigated. Thus, when comparing reports of antinociceptive efficacy of novel opioid drugs as well 
as when designing new compound evaluation strategies, the choice of mouse strain should also be 
taken into account.   
3- Assessment of opioid-induced respiratory depression 
Opioid-induced respiratory depression is a significant, potentially lethal, adverse effect of opioid 
agonists. MOR is expressed throughout the respiratory network of the brainstem, and recent studies 
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have demonstrated a key role of MOR expressed in nuclei including; the preBötzinger complex 
(preBötC), Kölliker-Fuse (KF), post-inspiratory complex, ventral respiratory column and the 
retrotrapezoid/parafacial nucleus (Bachmutsky, Durand, et al., 2020; Ramirez, et al., 2021; Varga, 
Reid, Kieffer, & Levitt, 2020). The relative importance of each respiratory brain nuclei to respiratory 
rhythmogenesis as well as their role in the response to exogenous opioids is currently debated 
(Ramirez, et al., 2021). While it is clear that the preBötC is an important site of action for opioid 
depression of respiration (Bachmutsky, Wei, Kish, & Yackle, 2020; Ramirez, et al., 2021), reports 
suggest both, an essential and a non-essential role of the preBötC for breathing rhythmogenesis 
(Gaspard Montandon & Horner, 2014) (Lalley, Pilowsky, Forster, & Zuperku, 2014). Further 
investigation is required to elucidate the importance of each nuclei both in the persistent control of 
respiration as well as in the effect of opioids on respiration. 
Due to its acute onset and relative ease of measurement, respiratory depression is one of the first 
adverse effects to be assessed in the characterisation of novel opioid agonists (Gillis, Gondin, et al., 
2020; Gillis, Kliewer, et al., 2020a; Hill, et al., 2018; Manglik, et al., 2016; Schmid, et al., 2017). Several 
non-invasive methods can be used to monitor respiration in rodents and determine respiratory 
parameters (for extended review of these methods see (Hoymann, 2007)).  
Whole body plethysmography. In whole body plethysmography (WBP), freely moving animals are 
placed in a closed chamber and the pressure fluctuations that occur during the breathing cycle are 
recorded. A pressure transducer monitors the pressure differences between the experimental 
chamber of the plethysmograph where the animal is placed and a reference chamber. Both chambers 
have a regulated flow of room air or a controlled combination of gas and the system is calibrated with 
known air volume changes. The three primary parameters derived from this technique are tidal 
volume (TV), the volume of each breath; respiratory frequency, the number of breaths per minute 
(BPM); and minute volume (MV), the composite of breath volume and frequency (Hill, et al., 2016). It 
is important to consider all three parameters as changes in MV may be due to a decrease in either 
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BPM, TV or both. For example, fentanyl-like drugs are thought to induce a decrease in TV through a 
separate action of muscle stiffness not commonly seen in other opioids  (Hill, Santhakumar, Dewey, 
Kelly, & Henderson, 2020) , which may contribute to their lethality. 
As respiration can be altered by stressed and quiescent states, measurements of respiration in WBP 
systems need to minimise the effect of these variables. Stress can induce a heightened respiratory 
baseline, and therefore, changes in respiration may indirectly be assessing the anxiogenesis and 
anxiolytic effects of the compounds tested (Lynch, et al., 2019). Minimising stress can be achieved 
with sufficient habituation of the animal to the WBP chamber (ideally the day prior to the experiment) 
(Hill, et al., 2016). As animals are unrestrained in the WBP chamber, it is possible for them to curl up 
and either sleep or enter a quiescent state. This can often be detected in vehicle administered groups 
(e.g. saline) when a significant reduction in respiration is observed while the treatment is known to 
have no effect on respiration. This effect appears to be mitigated by using larger WBP chambers such 
as those in comprehensive lab animal monitoring systems (CLAMS) (Reilley, et al., 2010) which provide 
a greater area for normal locomotor behaviour.  
Timing of experiments and housing conditions that maximise the activity of rodents can also help 
mitigate these confounds in smaller WBP chambers. These usually involve conducting measurements 
in the most active phases of the night cycle (Bains, et al., 2018) and housing the rodents on a reverse 
lit day-night cycle that allows experimentation during the night cycle of the animal, when they are 
naturally more active. Additionally, a mild hypercapnic stimulus can help maintain steady respiratory 
rates of mice without a significant induction of stress (as measured by corticosterone release (Hill, et 
al., 2016)) without apparent changes in the ability or sensitivity of opioids to induce respiratory 
depression (Hill, et al., 2018).  
Head-out plethysmography. In contrast to WPB, head-out plethysmography restrains the 
experimental animal in a plethysmograph chamber supplied with a controlled flow of air (Hoymann, 
2007) but leaves the head free through a sealed neck ring. As movement restraint is a significant 
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stressor (Lynch, et al., 2019), it is likely that the anxiolytic effect of opioids, in addition to their 
respiratory depressant effects, contribute significantly to the measurements using this approach. 
However, it may be the method of choice when additional more invasive methods are used for the 
study of lung and airway pathology.  
Pulse-oximetry. Unlike plethysmography, pulse-oximetry does not measure the mechanical actions of 
breathing in rodents but instead measures changes in blood oxygen levels. A decrease in blood oxygen 
saturation is used as a proxy for respiratory depression. The non-invasiveness and non-stressful 
properties of this method are advantages for the use of this approach to characterise the respiratory 
depressant effects of opioids in rodents (DeWire, et al., 2013; Faouzi, Varga, & Majumdar, 2020; 
Schmid, et al., 2017). It is however unclear how the respiratory parameters obtained using pulse 
oximetry relate to those obtained with the more established systems of whole body plethysmography 
and head out plethysmography. As mentioned above, minute volume, tidal volume as well as 
breathing frequency can be altered to differing extents by different opioids (Hill, et al., 2020).  
It is important to note that experimental assessments of respiratory depression do not have the same 
cut-offs as antinociception assays. This allows for estimates of efficacy and potency that are not 
subject to a defined maximal effect.  Moreover, it allows the assessment of the respiratory depressant 
potential of all novel opioids at higher doses than those providing effective antinociception, which 
defines the therapeutic window. Assessing the potential to induce respiratory depression is of 
relevance as this side effect underlies most opioid-overdose fatalities in humans.  
The impact of strain sensitivity on the respiratory depressant effects of opioids has recently been 
described (Table 2) (Bubier, et al., 2020; Young, et al., 2018). Of note, the reduced sensitivity of the 
129Sv1J mouse line to opioidergic responses has been suggested to underlie the arrestin-3 knock-out 
data (Bubier, et al., 2020; Kliewer, et al., 2020). 
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4- Assessment of opioid-induced constipation 
Opioid-induced constipation (OIC) is one of the most common side effects of opioid use in the clinic 
(McNicol, et al., 2003). Severe OIC has been reported in 40-95% of patients following the onset of a 
prescribed opioid regime (Pappagallo, 2001; Prichard & Bharucha, 2015; Swegle & Logemann, 2006), 
impacting the patient’s quality of life, decreasing compliance and often resulting in heightened pain 
(Hjalte, Berggren, Bergendahl, & Hjortsberg, 2010; Katz, 2002; Trescot, et al., 2008).  
Opioids act to inhibit acetylcholinergic neurons preventing the release of neurotransmitters and 
increasing longitudinal smooth muscle tone while decreasing propulsive activity (Brock, et al., 2012; 
Wood & Galligan, 2004). These effects are thought to be primarily mediated by the MOR as the effects 
are absent in MOR knock-out mice (Roy, Liu, & Loh, 1998). Importantly, both in animals and in humans, 
tolerance does not seem to develop within the GI tract actions of opioids, unlike antinociceptive 
tolerance, that requires increasing doses of opioids to provide the same level of analgesia (Müller-
Lissner, et al., 2017; Prichard & Bharucha, 2015). This was first identified in dogs (Plant & Miller, 1926) 
and has since been replicated across different species (Ling, Paul, Simantov, & Pasternak, 1989; 
Matsumoto, et al., 2016;).  Lack of tolerance to morphine-induced constipation has been shown from 
short (≤72hr) (Ross, Gabra, Dewey, & Akbarali, 2008) to longer (up to 10 days) administration periods. 
The use of peripherally restricted opioid antagonists, such as methylnaltrexone (Anissian, et al., 2012; 
Bader, Durk, & Becker, 2013; Michna, et al., 2011) or combination therapies of oxycodone and 
naloxone can be used to effectively treat OIC whilst retaining pain relief (Lowenstein, et al., 2009; 
Simpson, et al., 2008). Pre-clinically, the most common methods to measure OIC are faecal boli 
accumulation and glass bead expulsion.  
Faecal boli accumulation measures the overall production of faecal matter over time (typically 2-6h) 
following administration of opioids. This is usually done in under controlled feeding in order to 
measure food consumption against expulsion, and additionally a dye (e.g blue ink, charcoal) may be 
introduced into the diet to aid tracking of the bolus (Anand, et al., 2018).  
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The glass bead expulsion assay requires brief anaesthesia of the animal in order to insert a small glass 
bead into a defined distance in the colon (Matsumoto, et al., 2016). Following recovery from the 
anaesthetic, the time taken for the bead expulsion is measured. In this assay the opioid treatment can 
be administered before or after insertion of the glass bead. Whilst this assay is reliable and 
reproduceable, it is limited in its assessment of overall gut activity, as it only measures colonic transit 
effects. Comparatively, the faecal boli accumulation assay measures the effect of opioid inhibition 
throughout the entire gut, does not require the use of anaesthetics and is less invasive. However, it 
must also be considered that opioids can induce tolerance to differing degrees in colonic versus small 
and large intestinal transit in rodents (Matsumoto, et al., 2016; Mori, et al., 2013). Given these 
differences, the use of both assays in parallel may provide valuable information into regional 
differences in OIC.  
While the literature surrounding mouse strain differences in relation to OIC is sparse, a recent study  
compared two inbred mouse strains (A/J and C57BL/6J) and found that C57BL/6J mice were 
significantly more constipated following doses of morphine exceeding 40 mg/kg (Table 2)(Young, et 
al., 2018).  
 
5- Assessment of opioid-induced hyperalgesia and antinociceptive 
tolerance 
Chronic opioid use can lead to opioid-induced antinociceptive tolerance and hyperalgesia. Analgesic 
or antinociceptive tolerance corresponds to a progressive decrease of analgesia produced by a given 
opioid dose. This results in the need to increase the dose of opioids to provide a similar analgesic 
effect. Cellular and molecular mechanisms that underlie MOR regulation have been comprehensively 
reviewed (Williams, et al., 2013). Whilst some mechanisms of MOR regulation such as phosphorylation 
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(Doll, et al., 2011) and desensitisation (Bailey, et al., 2009) have been thoroughly studied, there are 
still significant gaps in our understanding of the molecular processes responsible for loss of MOR 
function after chronic exposure to opioids. In particular the role of arrestins, whilst clearly important 
in the development of opioid tolerance through MOR desensitisation, is still not fully understood 
(Bohn, Lefkowitz, & Caron, 2002; Kliewer, et al., 2019; Williams, et al., 2013). 
Opioid induced hyperalgesia (OIH) is characterised by a paradoxical increase in pain perception 
following the onset of opioid medication (Lee, Silverman, Hansen, Patel, & Manchikanti, 2011; 
Roeckel, Le Coz, Gaveriaux-Ruff, & Simonin, 2016). While most opioid drugs appear to induce OIH 
regardless of their intrinsic efficacy and mechanism of action (Angst & Clark, 2006; Araldi, Ferrari, & 
Levine, 2018; Compton, Canamar, Hillhouse, & Ling, 2012), the molecular mechanisms underlying this 
state of nociceptive sensitisation are complex and still not fully understood. The most important 
proposed mechanisms for OIH have been reviewed elsewhere (Lee, et al., 2011; Roeckel, et al., 2016). 
These mechanisms involve the NMDA-glutamatergic system, transient receptor potential channels V1 
and M8 (TRPV1 and TRPM8), and are influenced by several factors including genetic background and 
sex differences of experimental animals (Roeckel, et al., 2016). 
Experimentally, OIH and antinociceptive tolerance are measured through antinociception assays upon 
chronic administration of opioids, either by repeated administration or through osmotic minipumps 
(Hill, et al., 2018; Hill, et al., 2016; Koblish, et al., 2017). The most common antinociception assays 
used in this context are thermal stimulation (hot plate and tail flick) for antinociceptive tolerance and 
OIH, and mechanical stimulation for OIH assessment only (Koblish, et al., 2017; D.-Y. Liang, et al., 2006; 
Roeckel, et al., 2016). These allow the detection of significant changes in opioid-induced responses, 
and baseline latencies differences  of naïve versus chronically treated animals are readily observed (in 
particular for OIH). However, when assessing for hyperalgesia, higher temperatures or applied forces 
are an impediment to obtaining clear, meaningful data; the baseline nociceptive latency of the animal 
decreases as the thermal or physical intensity increases (Carroll, 1959; Carstens & Wilson, 1993; Ren 
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& Han, 1979), therefore the ability to detect a decrease in baseline threshold is also reduced at higher 
temperatures.  
The same inherent ethical limitations apply for assessment of hyperalgesia and tolerance as they do 
for antinociception assays. Moreover,  another limiting factor is the amplitude of the baseline 
nociceptive latency as an increase in the severity of the noxious stimulus will compromise the 
detection window even further upon the development of OIH (see above for the thermal example) 
(Jensen & Finnerup, 2014; Yalcin, Charlet, Freund-Mercier, Barrot, & Poisbeau, 2009). It is also of 
particular importance that multiple pain modalities are tested in the context of OIH as the 
development of OIH in patients is usually related to both chronic use of opioids as well as an underlying 
pain states (Burma, Leduc-Pessah, & Trang, 2017; Marrone, et al., 2017).  Other modalities include 
mechanical stimulation of pain responses (e.g. Von Frey filaments) (Koblish, et al., 2017), that can be 
performed in conjunction with pro-inflammatory treatments (e.g. carrageenan or capsaicin injections) 
(Luo, et al., 2008; Yalcin, et al., 2009) as well as neuropathic models of pain (e.g. nerve ligation assays) 
(Chen, et al., 2020). 
 
6- In vitro measurements of opioid pharmacology and their 
relationship with opioid-induced effects in vivo 
The antinociceptive, respiratory and gastrointestinal effects of opioid therapeutics are mainly caused 
by the activation of the MOR (Bachmutsky, Durand, et al., 2020; Matthes, et al., 1996; Roy, et al., 1998; 
Varga, et al., 2020). The MOR signals predominantly through the activation of Gai/o and bg proteins. 
MOR activation alters neurotransmitter release through presynaptic inhibition of voltage-gated 
calcium channels (VGCC) and inhibits neuronal activity through hyperpolarisation caused by post-
synaptic activation of G protein-coupled inwardly rectifying potassium (GIRK) channels. Moreover, G 
protein activation by MOR also results in inhibition of adenylate cyclase, resulting in decreased levels 
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of the second messenger cAMP. As with most GPCRs, the G protein signalling of MORs is regulated by 
phosphorylation of intracellular domains, arrestin binding and internalisation. Numerous in vitro 
assays are available for the detection of MOR signalling and regulation in cell lines. These assays 
include sensors to monitor receptor, G protein and GIRK channel activation, measurements of cAMP 
levels, recruitment of GRK and arrestins and receptor internalisation (Table 3). However, with the 
exception of electrophysiological approaches (Birdsong & Williams, 2020), application of these 
approaches for the detection of MOR signalling in neuronal cultures remains slightly more challenging.  
Despite the initial reports, recent evidence suggests that a clear separation of the signalling 
responsible for antinociceptive versus deleterious side effects of opioids is unlikely (Bachmutsky, Wei, 
Durand, & Yackle, 2021; Kliewer, et al., 2020; Kliewer, et al., 2019).  Antinociception, respiratory 
depression and constipation are all mediated by G protein activation by MOR and retained in arrestin 
KO mice (Bachmutsky, et al., 2021; Benyamin, et al., 2008; A. E. Conibear & Kelly, 2019; Gillis, Kliewer, 
et al., 2020b; Kliewer, et al., 2019; Matthes, et al., 1996; G. Montandon, et al., 2016; Valentino & 
Volkow, 2018).  However, this should not preclude the development of improved opioids that 
minimise adverse effects and provide wider therapeutic windows through other mechanisms or 
pharmacological properties different than biased agonism. For example, the role of ligand binding 
kinetics, as well as kinetic of effect has been proposed to underlie potential signalling differences 
among GPCR ligands (Klein Herenbrink, et al., 2016; van der Velden, Heitman, & Rosenkilde, 2020) 
although this does not seem to be the case for some novel opioids (Pedersen, et al., 2020). 
It has also been proposed that low intrinsic efficacy may provide an alternative explanation to the 
improved therapeutic profiles (Azevedo Neto, et al., 2020; Benredjem, et al., 2019; Gillis, Gondin, et 
al., 2020; Kelly, 2013).  This is supported by a recent study of clinically used opioids which found that 
intrinsic efficacy, rather than any G protein/β-arrestin bias, predicted the rate of reported adverse 
events (Benredjem, et al., 2019), and by the actions of the opioid buprenorphine, an extremely low 
efficacy MOR agonist with a ceiling effect in respiratory depression and reduced overdose risk (Dahan, 
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et al., 2006; Walsh, Preston, Stitzer, Cone, & Bigelow, 1994). In this context, the response of partial 
agonists, compounds with low intrinsic efficacy, is very sensitive to the presence of receptor reserve 
(also known as spare receptors). As such, partial agonists will display robust responses in systems with 
high receptor reserve, whilst in systems with lower receptor reserve they will produce a partial 
maximum response even at full receptor occupancy. As receptor reserve is a property of the tissue 
and of the agonist (Buchwald, 2019; S. J. Hill, 2006), it therefore follows that the same drug may elicit 
full or partial responses depending on the tissue receptor reserve. Although difficult to prove 
experimentally, these differences may explain the effects of low efficacy opioids (A. E. Conibear & 
Kelly, 2019; Gillis, Sreenivasan, & Christie, 2020; Pineyro & Nagi, 2021; Rajendra Uprety, et al., 2021). 
The presence of receptor reserve in the responses of opioid agonists is a pharmacological concept that 
has been thoroughly explored in cultured cell lines (Carliss, et al., 2009; Kelly, 2013) and utilised in 
electrophysiology (Lowe & Bailey, 2015). This is commonly assessed using irreversible antagonists 
(such as b-funaltrexamine (Takemori, Larson, & Portoghese, 1981), b-chlornaltrexamine (Portoghese, 
Larson, Jiang, Takemori, & Caruso, 1978) or methacinnamox (Broadbear, et al., 2000)) or genetic 
strategies to decrease receptor levels (Mizoguchi, et al., 1999; Singleton, et al., 2021; Sora, et al., 
2001).  
As mentioned above, measurements of antinociceptive efficacy are limited by the imposed cut-offs. 
However, given that low efficacy agonists such as buprenorphine or oliceridine provide effective 
antinociception, it may be suggested that some receptor reserve is present in this system. Similarly, 
as tail flick and hot plate assays do not measure identical responses, differences in receptor reserve 
may also be relevant to consider. The relationship between tolerance and receptor reserve as received 
particular attention (Chavkin & Goldstein, 1984; Mjanger & Yaksh, 1991; Williams, et al., 2013). A 
recent study, investigated the effect of irreversible antagonism in vitro and of reduced receptor 
expression in MOR +/- mice to  interrogate the antinociceptive tolerance of oliceridine  . Although a 
clear effect was observed in terms of ligand efficacy, oliceridine was still able to induce tolerance in 
mice expressing 50% less MOR than wild type (Singleton, et al., 2021).  
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Despite the potential to explain the different actions of opioids in different tissues, the impact of 
receptor reserve in the other physiological responses of opioids such as respiratory depression and 
constipation have not as yet been studied and compared with the effect of receptor reserve on 
antinociception. Future studies addressing the relevance of receptor reserve for the effects of opioids 
in vivo are likely to provide a much-needed framework of efficacy to drug discovery programs that 
may suggest some new strategies for the development of improved analgesics. 
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7- Concluding remarks 
• The inherent limitations in the experimental design of antinociception assays can influence 
determinations of efficacy of opioid drugs. When characterising novel opioid agonists, 
consideration should be taken into how these limitations affect the data.  
• Differential strain sensitivity to the effects of opioids (including the potential for differences 
in drug pharmacokinetics) needs to be thoroughly studied. This is not only important when 
comparing actions of opioids across laboratories, but also when considering the use of 
genetically modified mice.  
• Adverse side effects limit the therapeutic potential of novel opioid analgesics. It is important 
that all opioidergic behaviours induced by novel agonists are assessed at doses above those 
providing effective antinociception in order to understand the liabilities and risks associated 
with deliberate or accidental abuse. 
• Whilst early in vitro assessment of novel opioids provides valuable insight into their actions, 
these assays are limited in their ability to predict side effect liabilities. Early ex vivo 
characterisation of novel opioids in native tissue may provide better indications for side effect 
liability. Recent measurements of respiratory depression in zebra fish provides an example of 
an innovative higher throughput screen for novel opioids (Zaig, da Silveira Scarpellini, & 
Montandon, 2021).   
• Further assessments of the impact of receptor reserve and relative receptor expression levels 
across different tissues and animal strains are necessary to understand the relationship 
between efficacy and opioid-induced responses in vivo and provide a framework for the 
development of new opioid-based analgesics. 
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Figure 1 – Experimental considerations for the assessment of opioid pharmacology in vitro and in 
vivo. In vitro and in vivo characterisations of opioid action are both essential in drug discovery. 
However, important factors need to be considered to provide a consistent and systematic framework 
of opioid action. In vitro, compounds are tested for their binding to MOR, and for their ability to 
activate downstream signalling.  These assays need to take into account distinct variables than can 
affect the measured outcome. In vivo, candidates are usually first assessed for their antinociceptive 




Compound Antinociception assay - 
species 
Strain Temp & cut-off Reference 




Tail flick – mouse 
 
 
Hot plate – rat 
 












56oC, 30 sec 
54oC, 20 sec 
55oC, 30 sec 
 
52oC, 10 sec 
variable, 10 sec 
 
52oC, 30 sec 
 
variable, 15 sec 
50oC, 20 sec 
(DeWire, et al., 2013) 
(Gillis, Gondin, et al., 2020) 
(Mori, et al., 2021) 
 
(Altarifi, et al., 2017) 
(D. Y. Liang, Li, Nwaneshiudu, 
Irvine, & Clark, 2019) 
 
(DeWire, et al., 2013) 
 
(DeWire, et al., 2013) 
(Schwienteck, et al., 2019) 
TRV0109101 Hot plate – mouse 
 
Hot plate – rat 
 
Tail flick – rat 
 








56oC, 30 sec 
 
52oC, 30 sec 
 
variable, 15 sec 
 
0.4g only 
(Koblish, et al., 2017) 














55oC, 30 sec 
52.5oC, 30 sec 
54oC, 20 sec 
52.5oC, 30 sec 
 
56oC, 10 sec 
variable, 9 sec 
(Manglik, et al., 2016) 
(Kudla, et al., 2019) 
(Gillis, Gondin, et al., 2020) 
(Hill, et al., 2018) 
 
(Manglik, et al., 2016) 
(Kudla, et al., 2019) 
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Affective vs reflexive – hot 
plate – mouse 
 










(Manglik, et al., 2016) 
 
 
(Manglik, et al., 2016) 










52oC, 20 sec 
 
54oC, 20 sec 
 
49oC, 30 sec 
(Grim, et al., 2020; Schmid, et 
al., 2017) 
(Gillis, Gondin, et al., 2020) 
 
(Grim, et al., 2020; Schmid, et 
al., 2017) 




variable, 3 x 
baseline 
variable, 3 x 
baseline 
48oC, 30 sec 
variable, 10 sec 
(Varadi, et al., 2016) 
 
(Wilson, et al., 2021) 
(Kruegel, et al., 2019) 
7-OH 
Mitragynine 
Tail flick – mouse CD-1 
129S1 
variable, 3 x 
baseline 
variable, 10 sec 
(Varadi, et al., 2016) 
(Kruegel, et al., 2019) 
Mitragynine 
Pseudoindoxyl 
Hot plate – mouse 
 







55oC, 30 sec 
 
variable, 3 x 
baseline 
variable, 3 x 
baseline 
variable, 3 x 
baseline 
(Varadi, et al., 2016) 
 
(Varadi, et al., 2016) 
 
 
(Wilson, et al., 2021) 
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Table 1 – Opioid-induced antinociception assays used in MOR drug discovery. Summary of the 
antinociception assay, species, strain and cut-offs used for the evaluation of novel opioids.  
  
48oC, 30 sec 
Tianeptine Hot plate – mouse C57/BL6 50 or 55oC, 30 sec (Samuels, et al., 2017) 
MP-1208 & 
MP1207 
Tail flick – mouse  C57BL/6 55oC, 15 sec 
 
(R. Uprety, et al., 2021) 





Heat intensity 10 
(IITC Life Science), 
20 sec 
variable, 10 sec 
variable, 10 sec 
variable, 10 sec 
(Gomes, et al., 2013) 
 
(Faouzi, et al., 2020) 
MP135 Tail flick – mouse 
 
 





variable, 10 sec 
variable, 10 sec 
variable, 10 sec 
not given 
(Faouzi, et al., 2020) 
AT-201 Tail flick – mouse  ICR Radial beam 
(Stoelting, Wood 
Day, IL), 15 sec 




Tail flick – mouse  
Tail flick - rat 
CD-1 
Sprague-Dawley 
Variable, 9 sec 
Variable, 9 sec 
(Zadina, et al., 2016) 
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Drug Assay Strains Observations References 
Morphine Hot water tail flick 
– 49oC and 15 sec 
cutoff 
 
Four day escalating 
dose of morphine 




Strain – baseline (s) 
129P3 – 2.4 ± 0.1 
A – 2.4 ± 0.1 
AKR – 2.9 ± 0.2 
BALB/c – 3.1 ± 0.2 
C3H/He – 1.8 ± 0.1 
C57BL/6 – 2.2 ± 0.1 
CBA – 1.9 ± 0.1 
DBA/2 – 2.5 ± 0.1 
LP – 2.8 ± 0.1 
SJL – 2.2 ± 0.1 
SWR – 1.8 ± 0.1 
• Significant differences in 
baseline latencies. 
• Significant differences in the 
relative degree of tolerance 
(from 0.8 to 10.8 fold change 
in morphine ED50 values (day 1 
vs day 4)). 
 
 
Kest and Mogil, 
2002 
Morphine Hot water tail flick 
– 55oC and 10 sec 
cutoff 
 
Strain – baseline (s) 
SW – 2.7 ± 0.6 
129/SvEv – 3.5 ± 0.6 
• Significant differences in 
baseline latencies. 
• Differences in duration of 
antinociception (>6 hours in 
129/SvEv vs 2 hours in SW). 
• 129/SvEv mice were approx. 
10-fold more sensitive to 
morphine 
 
Crain and Shen, 
1999 
Morphine Hot water tail flick 
– 49oC and 15 sec 
cutoff 
 
Strain – baseline (s) 
129/J – 4.7 ± 0.2 
129/SvJ – 4.5 ± 0.1 
B6 – 2.6 ± 0.1 
• Significant differences in 
baseline latencies. 
• Right shifted dose-response 
curve to cumulative morphine 
in B6 mice. 
 
Mogil et al., 
1997 
 
Morphine LD50 determination 
by percent survival 
– measured by 
return to regular 
breathing 
Strain and sex – LD50 
(mg/kg) 
129S1/SvlmJ F – 631.3 
129S1/SvlmJ M – 664.2 
A/J F – 212.2 
A/J M – 225.2 
C57BL/6J F – 311.6 
C57BL/6J M – 254.3 
CAST/EiJ F – 882.2 
CAST/EiJ M – 429.9 
NOD/ShiLtJ F – 811.0 
NOD/ShiLtJ M – 588.8 
NZO/HILtJ F – 333.9 
NZO/HILtJ M – 324.4 
PWK/PhJ F – 261.0 
PWK/PhJ M – 359.1 
WSB/EiJ F – 526.4 
WSB/EiJ M – 695.6 
• Baseline respiration data not 
reported. 
• Significant differences in LD50 
values between strains and 
sex. 
 
Bubier et al., 
2020 








• Baseline values not compared 
between strains. 
• Enhanced sensitivity to 
morphine respiratory 
depression and significantly 
greater constipation in 
C57BL/6J mice vs A/J mice 




Table 2 – Strain differences in opioid-induced behaviours. Summary of the assays, strains and results 
reported in the studies addressing strain differences to opioid sensitivity.  
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Membrane potential assay, 
patch-clamp electrophysiology 
 




BRET, TR-FRET, imaging 
 
Western blot 
DeWire et al 2013, Gillis 
et al 2020, Pedersen et 
al, Mori et al 2021, 
Ehrlich et al 2019, Yudin 
et al 2019 
TRV0109101 b-arrestin recruitment  
 















pSer375 Western blot 
(Koblish, et al., 2017) 




























BRET, GTPgS binding, FRET 
 
Membrane potential assay, 
patch-clamp electrophysiology 
 









(Manglik, et al., 2016) 
(Gillis, Gondin, et al., 
2020) 
(Hill, et al., 2018) 
Yudin et al 2019 
 















(Grim, et al., 2020; 
Schmid, et al., 2017) 






Table 3 – In vitro signalling assays used in MOR drug discovery. Summary of the cell signalling assays 
commonly used for opioid drug discovery. Fsk; forskolin, ORs; opioid receptors, BRET: Bioluminescence 
Resonance Energy Transfer, FRET; Förster Resonance Energy Transfer, TR-FRET; Time-Resolve FRET; GIRK 




G protein activation 
 
GIRK channel activation 
 








BRET, GTPgS binding  
 
Membrane potential assay 
 






Mitragynine G protein activation 
 
b-arrestin recruitment  
CHO GTPgS binding 
 
DiscoverX PathHunter 
(Varadi, et al., 2016) 
 
(Wilson, et al., 
2021)(Wilson, et al., 
2021)(Wilson, et al., 
2021)(Wilson, et al., 
2021)(Wilson, et al., 
2021)(Wilson, et al., 




G protein activation 
 
b-arrestin recruitment 
CHO GTPgS binding 
 
DiscoverX PathHunter 
(Varadi, et al., 2016) 
Mitragynine 
Pseudoindoxyl 
G protein activation 
 
b-arrestin recruitment 
CHO GTPgS binding 
 
DiscoverX PathHunter 
(Varadi, et al., 2016) 
 
Tianeptine G protein activation 
 
Inhibition of Fsk-induced 
cAMP accumulation 












G protein activation 
 






BRET, GTPgS binding 
 
GloSensor 
(R. Uprety, et al., 2021) 
CYM51010 b-arrestin recruitment 
 
G protein activation 
U2OS DiscoverX PathHunter 
 
BRET, GTPgS binding 
(Gomes, et al., 2013) 
 
(Faouzi, et al., 2020) 
MP135 b-arrestin recruitment 
 
G protein activation 
U2OS DiscoverX PathHunter 
 
BRET, GTPgS binding 
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